Object Pharma, Inc

Established in 1940, Grifols USA develops and manufactures a variety of medical devices and diagnostic systems for the health care industry. It distributes products in the fields of transfusion, blood banking, clinical analysis and specialty therapy. The company provides plasma derivatives and blood coagulation analyzers. Its products are used for the treatment of oncology and pediatric dysfunctions, as well as offers solutions in the area of pain management. The company supplies products under the Gri-fill, Misterium, Alphanate, AlphaNine, Profilnine, Flebogamma, Triturus, Albutein and Human Albumin Grifols brands. It offers technical support, marketing, plasma screening, and research and development services. Grifols USA is a part of Grifols, S.A., which is a group of companies that serves health care professionals and patients in more than 90 countries worldwide.

Cirius Therapeutics is a biopharmaceutical company based in San Diego, CA, specializing in the development of innovative treatments for NASH (nonalcoholic steatohepatitis). Their dedicated team of experts is committed to advancing scientific research and publishing cutting-edge findings in the field. With a focus on NASH, Cirius Therapeutics aims to address the unmet medical needs of patients through their advanced scientific approach. Their board of directors oversees strategic decision-making to drive the company's mission forward.Generated from the website

Prometheus Biosciences is a pioneering biotech company based in San Diego, CA, dedicated to revolutionizing the treatment of immune-mediated diseases, starting with inflammatory bowel disease (IBD). With their unique precision approach, they leverage cutting-edge data science and a vast collection of patient data to develop breakthrough precision therapeutic and companion diagnostic products, aiming to end the trial-and-error treatment cycle. By analyzing over 200,000 patient samples and integrating genetics, serologics, transcriptomics, and longitudinal clinical data, Prometheus Biosciences has gained unprecedented insights into the immunological networks driving immune-mediated diseases. Through their innovative Prometheus360 discovery engine, they harness the power of machine learning to continually identify new drug targets and disease biomarkers, ultimately delivering targeted treatments for patients and transforming the field of precision medicine.Generated from the website